Gladden Brian T purchased $100K of XRAY

Gladden Brian T purchased 9,985 shares of DENTSPLY SIRONA Inc. (XRAY) at $10.02 ($0.10M total) on 2026-06-15.

Original reporting
SEC EDGAR · Gladden Brian T
Published Jun 15, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XRAY
Bullish
low confidence
Mentioned
$XRAY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XRAYBullishLow
01

Why it matters

A director’s open-market purchase provides incremental sentiment information but does not change the company’s fundamentals in the text provided.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still treat it as lower-signal without corroborating fundamental news.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15 (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

$XRAYBullishLow confidence
Context

Dentsply Sirona director Brian T Gladden filed an open-market purchase of 9,985 shares at $10.0150 on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect is typically small and fades unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a routine insider transaction (director open-market purchase) with no accompanying guidance, deal, or operational update.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys are often discretionary and may reflect diversification, liquidity planning, or routine compensation-related behavior rather than a new bullish thesis.

Key entities

  • Dentsply Sirona Inc.

    Subject of the SEC Form 4 insider transaction disclosure (XRAY).

  • Gladden Brian T

    Director who purchased 9,985 shares on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

$XRAYMedAI 8/10

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.